On 20 October 2004, orphan designation (EU/3/04/240) was granted by the European Commission to Eisai Limited, United Kingdom, for rufinamide for the treatment of Lennox-Gastaut syndrome.
Rufinamide has been authorised in the EU as Inovelon since 16 January 2007.
The sponsorship was transferred to Eisai GmbH - Germany, in June 2018.
|Disease / condition||
Treatment of Lennox-Gastaut syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.